Alendronate in patients with calcium nephrolithiasis and loss of bone mass
- 67 Downloads
Our purpose is to show the effect of alendronate on patients with recurrent calcium lithiasis and loss of bone mass, and to observe their progress with analytical and densitometric markers.
We present a unique cohort (before and after study) of 15 patients with recurrent calcium nephrolithiasis and loss of bone mass treated for three years with 70 mg sodium alendronate weekly. The sample is divided into two groups by sex (5 men and 10 women, aged 35–65 years). We assessed clinical progress of both bone and lithiasic disease and urine and plasma markers of both pathologies.
We obtained a significant decrease in calcuria levels after 3 years of treatment (15.1 vs. 10.1; p=0.01), fasting calcium/creatinine quotient (0.16 vs. 0.10; p=0.002), and β-crosslaps (0.596 vs. 0.501; p=0.01). Moreover, we observed a disease stabilization in 14 of the 15 patients (93.3%), and, in all patients, bone mineral density had improved. Neither side effects nor losses of patients were observed after 3 years of treatment.
The use of weekly alendronate in patients with recurrent calcium lithiasis and loss of bone mass is safe and effective, curbs lithiasic disease progression, and improves bone mineral density.
KeywordsAlendronate Calcium stones Bone density loss
Unable to display preview. Download preview PDF.
- Cipriani Thorne E. Osteoporosis: Consideraciones diagnosticas y terapeuticas. Rev Med Hered. 2004; 15:101–107Google Scholar
- Adrover Rigo M, Juste Diez de Pinos JL, Tuset Creus M, Codina Jane C, Ribas Sala J. Revision clínica de la utilización de los bifosfonatos. Farm Hosp. 2000; 24:74–82Google Scholar
- Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24:237–244Google Scholar
- Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001; 86:1116–1125PubMedCrossRefGoogle Scholar
- Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009; 24:1472–1477PubMedCrossRefGoogle Scholar